Aflibercept 8 mg Receives Approval Extension for Retinal Vein Occlusion Macular Edema in Germany
Aflibercept 8 mg has been granted an expanded approval in Germany, effective January 2026, for the treatment of visual impairment stemming from macular edema associated with retinal vein occlusion (RVV). This advancement offers a potentially reduced treatment burden for patients while maintaining effective visual acuity gains.The approval is based on compelling data from the QUASAR study, which demonstrated that aflibercept 8 mg achieved it’s primary endpoint at week 36, exhibiting comparable improvements in visual acuity to the existing 2 mg formulation.
Notably, the QUASAR study indicated that these positive outcomes were achieved with fewer injections, and across all subtypes of RVV. A panel of experts suggests this expanded indication provides a promising option for patients with RVV, offering the potential for both improved visual outcomes and enhanced disease management with a decreased frequency of treatment. This development represents a important step forward in the therapeutic landscape for RVV-related macular edema, potentially improving the quality of life for affected individuals.
Worth a look